Testing for Rare Genomic Alterations in Colorectal Cancer
Michael J. Overman, MD, discusses the advances in testing for rare genomic alterations in colorectal cancer.
Michael J. Overman, MD, professor at The University of Texas MD Anderson Cancer Center, and committee vice chair at The University of Texas MD Anderson Cancer Center – ECMS in Houston, Texas, discusses the advances in testing for rare genomic alterations in colorectal cancer (CRC).
Historically, experts in the field focused on KRAS mutational status, RAS status, and anti-EGFR therapies, Overman explained. Over the years, mindsets have expanded to also consider alterations like BRAF, HER2, and prognostic factors like mismatch repair deficiency. Many of these are now mandated for testing in CRC, Overman says.
There are also rare genomic alterations that fall under the gene fusion category that have available treatment options and should be considered for testing, according to Overman.
Checkpoint Inhibitors Deliver Longer OS in PPP2R1A-Mutated Endometrial Cancer vs Wild-Type Disease
April 7th 2025Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed inactivating PPP2R1A mutations vs patients with wild-type PPP2R1A.
Read More
